ArticleAIMS medical science
Application of
Article in AIMS medical science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 67 citations in OpenAlex.
- Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212 (EJNMMI radiopharmacy and chemistry · 2026Article
- PreclinicalJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Recent advances and current landscape of software tools for image analysis and dosimetry in nuclear medicine.EJNMMI physics · 2026Review
- Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside.Theranostics · 2026Review
- In silico assessment of cellular damage from Lu-177, Ac-225, and Pb-212 therapeutic radionuclides.Medical physics · 2025Article
- Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy.Molecular cancer therapeutics · 2025Article
- Cytotoxicity ofEJNMMI radiopharmacy and chemistry · 2025Article
- Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025Review
- Antigen targeting and anti-tumor activity of a novel anti-CD146Scientific reports · 2024Article
- Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Targeted Alpha-Particle Therapy: A Review of Current Trials.International journal of molecular sciences · 2023Review
- Optimized production, purification, and radiolabeling of theScientific reports · 2023Article
- An Experimental Generator for Production of High-PurityJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Advancing Chelation Strategies for Large Metal Ions for Nuclear Medicine Applications.Accounts of chemical research · 2022Article
- Synthesis of Ionizable Calix[4]arenes for Chelation of Selected Divalent Cations.Molecules (Basel, Switzerland) · 2022Article
- Article
- Preclinical evaluation of [European journal of nuclear medicine and molecular imaging · 2021Article
- Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancers · 2021Review
- Diacerein, an inhibitor of IL-1β downstream mediated apoptosis, improves radioimmunotherapy in a mouse model of Burkitt's lymphoma.American journal of cancer research · 2021Article
- Perspectives on metals-based radioimmunotherapy (RIT): moving forward.Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Targeted α-particle therapy (TAT), in which an α-particle emitting radionuclide is specifically directed to a biological target, is gaining more attention to treat cancers as new targets are validated. Bio-vectors such as monoclonal antibodies are able to selectively transport α-particles to destroy targeted cancer cells. TAT has the potential for an improved therapeutic ratio over β-particle targeted conjugate therapy. The short path length and the intense ionization path generated render α-emitters suitable for treatment and management of minimal disease such as micrometastases or residual tumor after surgical debulking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.